Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

L. Khoja, E. G. Atenafu, S. Suciu, S. Leyvraz, T. Sato, E. Marshall, U. Keilholz, L. Zimmer, S. P. Patel, S. Piperno-Neumann, J. Piulats, T. T. Kivela, C. Pfoehler, S. Bhatia, P. Huppert, L. B. J. Van Iersel, I. J. M. De Vries, N. Penel, T. Vogl, T. ChengG. Fiorentini, F. Mouriaux, A. Tarhini, P. M. Patel, R. Carvajal, A. M. Joshua*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1370-1380
Number of pages11
JournalAnnals of Oncology
Volume30
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • meta-analysis
  • uveal melanoma
  • trial design
  • survival benchmarks
  • STAGE-IV MELANOMA
  • PHASE-II TRIAL
  • GEMCITABINE PLUS TREOSULFAN
  • LIVER METASTASES
  • CHEMOEMBOLIZATION TACE
  • CHOROIDAL MELANOMA
  • 1ST-LINE TREATMENT
  • INTRAARTERIAL
  • TEMOZOLOMIDE
  • COMBINATION

Cite this